Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details)

v3.8.0.1
Commitments and Contingencies (Details) - AbbVie Biotherapeutics Corp [Member] - USD ($)
 1 Months Ended 9 Months Ended
Jul. 24, 2012
Sep. 30, 2017
Summary of milestone payment    
Milestones Payments   $ 7,750,000
Phase 1 Clinical Trial of a licensed product [Member]    
Summary of milestone payment    
Milestones Payments $ 750,000 $ 750,000
Milestones Date Met   July 2012
Phase 2 Clinical Trial of a licensed product [Member]    
Summary of milestone payment    
Milestones Payments   $ 750,000
Milestones Date Met   September 2016
Phase 3 Clinical Trial of a licensed product [Member]    
Summary of milestone payment    
Milestones Payments   $ 1,500,000
Milestones Date Met   In future
Biological License Application filing with U.S. FDA [Member]    
Summary of milestone payment    
Milestones Payments   $ 1,750,000
Milestones Date Met   In future
First commercial sale [Member]    
Summary of milestone payment    
Milestones Payments   $ 1,500,000
Milestones Date Met   In future
After first net sales [Member]    
Summary of milestone payment    
Milestones Payments   $ 1,500,000
Milestones Date Met   In future